# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-051310
Filing Date
2024-05-01
Accepted
2024-05-01 16:22:06
Documents
84
Period of Report
2024-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | rgen-20240331.htm iXBRL | 10-Q | 1911497
2 | EX-31.1 | rgen-ex31_1.htm | EX-31.1 | 13719
3 | EX-31.2 | rgen-ex31_2.htm | EX-31.2 | 13468
4 | EX-32.1 | rgen-ex32_1.htm | EX-32.1 | 16506
| Complete submission text file | 0000950170-24-051310.txt |  | 10426879

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | rgen-20240331.xsd | EX-101.SCH | 1761392
87 | EXTRACTED XBRL INSTANCE DOCUMENT | rgen-20240331_htm.xml | XML | 2022605

Mailing Address 41 SEYON STREET BUILDING 1, SUITE 100 WALTHAM MA 02453
Business Address 41 SEYON STREET BUILDING 1, SUITE 100 WALTHAM MA 02453 7814499560
REPLIGEN CORP (Filer) CIK: 0000730272 (see all company filings)

EIN.: 042729386 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-14656 | Film No.: 24903364
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)